Status:
WITHDRAWN
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Driver
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients (older than 18 years at time of treatment) with high risk prostate cancer who were treated with proton therapy at UFHPTI/Department of Radiation Oncology
- Patients treated between 6/10/2010 through 4/26/17 with at least 2 years follow up
Exclusion
Key Trial Info
Start Date :
December 7 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03296124
Start Date
December 7 2017
End Date
September 1 2020
Last Update
November 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida Proton Therapy Institute
Jacksonville, Florida, United States, 32206